BCL2 and meningioma: Therefore, we examined the sensitivity of malignant meningioma cells treated with gemcitabine and everolimus to the BCL-2-specific inhibitor, venetoclax, and the BCL-xL-specific inhibitors, A-1331852 and A-1155463 [28].